Allegheny Health Network Pioneers Personalized Medicine through Genetics and Precision Cancer Care

December 16, 2023

Unlocking Personalized Medicine with Allegheny Health Network's Center for Genetics and Precision Medicine

Partner: Allegheny Health Network

Innovations at the forefront of healthcare have led us to a new era of personalized medicine. Allegheny Health Network AHN has embraced this advancement by establishing its Center for Genetics and Precision Medicine at the AHN Cancer Institute, revolutionizing cancer care through targeted therapies based on individual genetic profiles.

The state-of-the-art facility is harnessing the power of gene sequencing technology to dissect the genomic blueprint within cancer cells. By uncovering mutations that drive tumor growth, researchers are providing physicians with a precise map for diagnosing, treating, and managing cancers in a manner that is uniquely tlored to each patient's needs.

We're implementing molecular testing as part of our standard care protocol, shared William LaFramboise, PhD, AHN Cancer Institute professor and chief genomics technology officer. This enables us to delve into the molecular underpinnings of cancer, identifying actionable targets and customizing treatments that can potentially outwit tumor evolution.

Through advanced genomic profiling of tumors and blood samples, researchers are extracting DNA sequences that reveal genetic abnormalities. These findings offer a critical insight for clinicians in tloring therapies that match the specific vulnerabilities of each patient's cancer cells.

Precision medicine empowers us to stay one step ahead of cancer progression, sd David Bartlett, MD, system chr of AHN Cancer Institute. With the capability to detect and analyze genetic alterations before or after treatment, we can gn a clearer picture of how cancer evolves in response to therapies.

The Molecular Tumor Boarda collaborative team including experts from various disciplinesplays a pivotal role in integrating these data-driven insights with clinical expertise. They review genomic information alongside medical records and patient outcomes to craft personalized treatment plans that consider both biological nuances and potential clinical trials.

Moreover, AHN's genomics initiative exts beyond individual care pathways by building a comprehensive biorepository of genomic data from patients who previously underwent molecular profiling by external vors. This resource, combined with new genomic findings, contributes to a vast knowledge base on cancer types prevalent in the region.

Through this wealth of information, Dr. LaFramboise elucidated, we m to identify patterns and risk factors for cancers that could affect entire communities. By sharing these insights with healthcare providers across Western Pennsylvania and beyond, we strive to improve detection rates and outcomes for everyone.

In addition to advancing clinical care through precision medicine, Allegheny Health Network is at the forefront of research and innovation in oncology. The network's contributions not only enhance patient care but also inform future directions in cancer treatment and prevention.

series will delve into AHN Cancer Institute’s groundbreaking initiatives, showcasing their commitment to transforming the field of oncology through cutting-edge science and compassionate care.

Additional Resources:

• Dr Miller on Patient Advocacy in Gynecologic Oncologylink

• Dr Coopey’s Insights on Ger Disparities in Breast Cancerlink

• The AHN Cancer Institute's Pancreatic Cancer Programlink

Contact Information:

2 Commerce Drive

Cranbury, NJ 08512

609-716-7777

? MJH Life Sciences - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Home About Us News Contact
This article is reproduced from: https://www.onclive.com/view/decoding-genes-to-target-cancer

Please indicate when reprinting from: https://www.81le.com/Tumor_Cancer/AHN_Precision_Medicine_Research.html